Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: A meta-analysis
Chloe Charlwood, Jenika Chudasama, A. L. Darling, Hugh Logan Ellis, Martin Whyte
Abstract
AIMS: There has been uncertainty whether SGLT2 inhibition predisposes to hyperkalaemia or is protective from it. We therefore performed a meta-analysis to assess effects of SGLT2 inhibition on serum-potassium and hyperkalaemia-events in T2DM. METHODS: statistic assessed statistical heterogeneity. Meta-analyses were performed using Cochrane-RevMan with two outcomes: i) Odds ratio (OR) of hyperkalaemia-events between SGLT2 inhibitor and placebo (fixed-effects), ii) Mean difference (MD) in change from baseline potassium between SGLT2 inhibitor and placebo (random-effects). RESULTS: of 89%. CONCLUSIONS: Use of SGLT2 inhibitors in T2DM reduced odds of inducing hyperkalaemia but had a minimal effect of lowering serum potassium.